Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

Published

Journal Article

Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. Phase II clinical trials of pradefovir have been completed.

Full Text

Cited Authors

  • Tillmann, HL

Published Date

  • August 2007

Published In

Volume / Issue

  • 8 / 8

Start / End Page

  • 682 - 690

PubMed ID

  • 17668370

Pubmed Central ID

  • 17668370

International Standard Serial Number (ISSN)

  • 1472-4472

Language

  • eng

Conference Location

  • England